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Background/Purpose: Patients with chromosomal translocation are highly vulnerable to produce unbalanced gametes that result in recurrent miscarriages, affected offspring, or infertility. Preimplantation genetic diagnosis (PGD) with blastomere biopsy and fluorescent in-situ hybridization (FISH) has been used to select normal/balanced embryos for transfer. However, FISH is inherent with some technical difficulties such as cell fixation and signal reading. Here we introduce a strategy of PGD using blastocyst biopsy and array comparative genomic hybridization (aCGH) for reproductive problems of patients with chromosomal translocation.
Methods: Twelve patients diagnosed as having chromosomal translocation who underwent PGD cycles were included in this single-center observational study. Blastocyst biopsy was performed and biopsied blastocysts were cryopreserved individually. Testing was performed with aCGH, and the euploid embryos were transferred in the following thawing cycles.
Introduction
Chromosomal rearrangements are the most common structural chromosome abnormalities, with an estimated 0.19% prevalence in the general population, and even higher in certain populations, such as 5% in patients who underwent in vitro fertilization (IVF) treatments and experienced recurrent miscarriages and repeated IVF failure. 1 Carriers of balanced chromosomal rearrangements usually have normal phenotype, but have a high risk (19e77%) of producing chromosomally unbalanced gametes following abnormal meiotic segregation, depending on the type of chromosome aberration, the chromosomes involved, and the number and location of breakpoints. 2 This may result in infertility, recurrent miscarriages (spontaneous or induced after prenatal diagnosis), or delivery of an affected offspring with mental retardation or other congenital abnormalities. 1, 3 In the past, these patients could only have prenatal diagnosis to confirm the karyotype of the fetus after considerable time and effort to get pregnant, and they may even suffer more if the results show an unbalanced translocation. Alternatively, they might decide to choose a sperm donor or oocyte donor after repeated failure to achieve a normal pregnancy. Sometimes this may cause infertility and usually the couples experience repeated IVF failures and enormous psychological stress when they seek help from assisted reproductive technologies (ART). 3, 4 Preimplantation genetic diagnosis (PGD), combined with ART, can identify and select only chromosomally normal or balanced embryos to be transferred to the uterus. 5e7 It has been shown that PGD can significantly shorten the time to achieve a successful live birth from 4e6 years to <4 months, and decrease the incidence of miscarriage from >90% to <15% in the translocation carriers. 4, 8 This offers an alternative for the carriers in that they do not need to suffer from the tremendous grief of repeated early pregnancy losses or to terminate the affected pregnancy once revealed by the prenatal diagnosis. 4 The most widespread method of PGD for translocation is eight-cell stage embryo biopsy with fluorescence in situ hybridization (FISH) followed by Day 4 or Day 5 embryo transfer (ET) in a fresh IVF cycle.
9e11 However, the FISH method has some drawbacks including difficulties in fixation of blastomeres, hybridization failure, signal overlap, and signal splitting that can affect the accuracy of the interpretation. 12, 13 Newer techniques have been proposed to increase the diagnostic accuracy and efficiency, such as the application of polymerase chain reaction (PCR)-based PGD protocol, metaphase comparative genomic hybridization (CGH), and array CGH (aCGH). 1, 3 However, FISH and PCR-based methods only allow identification for a limited number of chromosomes, whereas CGH and aCGH can detect all 24 chromosomes. Although FISH methods are cheaper and can usually provide translocation screening, they usually need workup to determine the appropriate probes to be utilized for the often denovo rearrangements specific to the individual. Also, they do not allow for comprehensive aneuploidy screening. 1, 3, 12 Furthermore, in some cases commercial FISH probes are not available for the chromosome of interest due to cross hybridization with other regions. However, these patients can now benefit from aCGH as it is genome wide and does not require a specific test to be developed. 1, 3, 11, 12 The most suitable methodological design in the practice of PGD has not been well established. Polar body biopsy can be used for the genetic analysis of the oocyte but is not feasible for detecting male genetic problems. In contrast to eight-cell embryo biopsy, blastocyst biopsy provides more cells than the cleavage-stage biopsy (5e10 cells vs. 1 or 2 cells) for genetic analysis and may potentially increase the diagnostic accuracy. Both of them allow analysis of chromosomes from maternal and paternal origin. 6, 7, 14 Here we report a strategy of PGD using blastocyst biopsy, aCGH, and thawed ET for patients with chromosomal translocation. We analyzed the data of clinical treatments. The preliminary results indicate that this strategy is an important option for these patients.
Materials and methods

Study population
This was a single-center observational study. Patients who were diagnosed as having chromosomal translocations and requested PGD at National Taiwan University Hospital from January 2011 to April 2012 were included. A comprehensive counseling was provided by an experienced clinical geneticist and reproductive endocrinologist to each couple prior to starting the treatment. The participants were well informed on the procedures of IVF and PGD with aCGH, its efficacy, and limitations. Data on the parental age, family and reproductive history, reasons for karyotyping, and their specific types of chromosomal aberration were recorded. Written informed consent was obtained from each couple. This study was approved by the Ethics Committee of National Taiwan University Hospital.
For each PGD cycle the following data were recorded: the number of retrieved oocytes; number of mature oocytes (metaphase II oocytes); number of fertilized oocytes; number of biopsied embryos; location and size of chromosomal aberrations in each diagnosed embryos; and pregnancy outcomes after ET. The primary outcome measurements were diagnostic rate, euploidy rate, and ongoing pregnancy rate.
Blastocyst biopsy and cryopreservation of biopsied embryos
Ovarian stimulation was performed with either gonadotropin-releasing hormone (GnRH) antagonist protocol or GnRH agonist short protocol as described previously.
15e17 Retrieval of oocytes was performed vaginally. In order to avoid contamination from sperm or surrounding cumulus cells, intracytoplasmic sperm injection was performed in every case. Embryos that had reached blastocyst stage were biopsied at trophectoderm on either Day 5 or Day 6, based on the method described by Chen et al. 18 Five to 10 trophoblasts were aspirated from each blastocyst and were transferred to a separate PCR tube. The biopsied blastocyst was treated with cryoprotectants and transferred onto a Cryotop (Kitazato Supply Co., Fujinomiya, Japan) individually. 19 
Whole genome amplification and aCGH
The multiple displacement amplification method using SurePlex Whole Genome Amplification (WGA) Kit (BlueGnome, Cambridge, UK) was performed for WGA, according to the manufacturer's instruction. This technology is based on random fragmentation of genomic DNA and subsequent amplification by PCR utilizing flanking universal priming sites. Amplified sample DNA and control DNA were then labeled with Cy3 and Cy5 fluorophores respectively and cohybridized competitively to a bacterial artificial chromosome microarray platform (24sure; BlueGnome). The times for labeling and hybridization were 16 hours and 3 hours, respectively. The resolution of the microarray was estimated at 2e5 Mbp depending on the specific type and location of a genetic aberration. The hybridized 24sure slides were then washed to remove unhybridized DNA with Hybex Microarray Incubation System (BlueGnome). Microarray slides were dried in the vacuum centrifuge and then scanned. The hybridized fluorophores were excited and the resulting images of the hybridization read and stored by a two-channel laser scanner. Finally the results were analyzed and the whole chromosomal loss or gain reported with BlueFuse Multi software (BlueGnome).
Thawed ET
When clear results of aCGH were seen, euploid blastocysts were thawed and transferred with two different protocols of endometrial preparation. One was natural ovulation cycle that no additional gonadotropin or synthesized ovarian steroids were given prior to ovulation and the embryos were thawed 6 days after observing serum luteinizing hormone surge. Another endometrial preparation consisted of estradiol valerate (Estrade; Synmosa, Taipei, Taiwan) and 8% intravaginal progesterone gel (Crinone; Merck Serono, Geneva, Switzerland) supplement and the embryos were thawed on the sixth day of progesterone administration. 20 Patients with a positive pregnancy test continued with estrogen and progesterone supplementation until 12 weeks' gestation.
ET was performed 3e4 hours after warming, as described previously. 20 One or two embryos were transferred/cycle. Biochemical pregnancy was confirmed with serum b-human chorionic gonadotropin test 12 days after ET. Implantation was determined by the presence of a gestational sac according to transvaginal ultrasound at a gestational age of 5 weeks. The ongoing pregnancy was defined as presence of fetal heart beat until 12 weeks of gestation.
Confirmation of karyotype of fetus with conventional prenatal diagnosis
In cases where pregnancies were achieved, conventional prenatal diagnosis with chorionic villi sampling (CVS) or amniocentesis was offered to confirm the karyotype of the fetus.
Statistical analyses
Statistical analysis was performed using SPSS version 17.0 software (SPSS Inc., Chicago, IL, USA). Categorical data are presented as number of events/cases and percentages for each group of interest. Continuous data are presented as mean and standard error of the mean.
Results
A total of 12 patients diagnosed with a variety of chromosomal translocation, including 11 with reciprocal translocation and one with Robertsonian translocation, were enrolled. The age, karyotype, the reason for karyotyping, pregnancy history of each couple are listed in Table 1 and  Table 2 . The reasons for karyotyping included six cases of repeated miscarriages, three cases of oligospermia, two cases of previously affected child, and one case of repeated IVF failure. The case with repeated IVF failure underwent a total of eight IVF cycles due to endometriosis factor prior to karyotyping and all failed. The karyotypes of the spouses were all normal.
Previous pregnancy history of 12 couples showed a total of 24 previous pregnancies. These resulted in 20 cases of spontaneous abortions prior to 12 weeks of gestational age, one case of intrauterine fetal demise at second trimester, and one case of elective termination of pregnancy at second trimester due to abnormal karyotyping by prenatal diagnosis. There was one normal live birth, which was conceived via conventional IVF treatment. The other live birth was affected with unbalanced autosomal translocation, showing congenital hypotonia and developmental delay.
The characteristics and outcomes of PGD cycles are shown in Table 3 . A total of 12 PGD cycles were performed with blastocyst biopsy and aCGH, followed by cryopreservation and thawed ET in the next menstrual cycle. diagnostic efficacy was 90.2% (55 results from a total of 61 samples) and the main reason for nondiagnosis was amplification failure.
Thawed ET was performed in nine couples following PGD cycles as in Table 4 . Three couples did not have normal/ balanced embryos. In total 15 normal or balanced embryos were thawed and 14 survived with a survival rate of 93.3%. Seven of 14 transferred embryos (50%) implanted, resulting in three live births and another three ongoing pregnancies. The mean number of transferred embryos was 1.4. The ongoing pregnancy rate was 60%/transfer cycle and 50%/ PGD cycle. The prenatal diagnosis with CVS reconfirmed the results of PGD/aCGH in all six pregnant women. There were three euploid embryos still cryopreserved for three couples, which could be transferred in the future. The detailed karyotypic information of each diagnosed embryo is listed in Table 5 .
Discussion
Our study demonstrates an effective strategy of PGD treatment for the reproductive problems of carriers of chromosomal translocations using blastocyst biopsy, aCGH, and thawed ET. Reviewing the literature, we found two other studies using aCGH to perform PGD for the carriers of chromosomal translocations. 1, 3 The diagnostic efficacy ranged from 90% to 93.5% in our study and the other two studies, which were comparable with those studies using FISH.
1e3, 21, 22 However, the clinical pregnancy rate seemed to be higher in the studies using aCGH, which were 42.9%/ PGD cycle by Fiorentino et al, 3 and 50% in our study. The reported clinical pregnancy rate in those studies using FISH ranged from 16% to 33%. 1e3,9,21e25 More interestingly, no case of miscarriage took place in our study and the other two studies using aCGH, whereas the reported miscarriage rates of the studies using FISH were 2e37.5% in the literature.
1e3,9,21e25 The elevation of clinical pregnancy rate and elimination of miscarriage in our study and Fiorentino et al's study might be due to the advantage of the comprehensive 24 chromosomal aneuploidy screening provided by aCGH. More studies will be needed to verify our preliminary result. aCGH using 24sure technology was performed for genetic analysis in our study. It provides 24-chromosome analysis to screen both the translocation and all the other aneuploidies, instead of a set of usually 5e12 chromosomal probes used by traditional FISH method. It can detect spontaneous aneuploidy other than specific translocation derived from carriers. 26, 27 In our study, 10.9% (6/55) embryos were normal or balanced at the chromosomes involved in the translocation but were found to have other de novo aneuploidies. They will be misdiagnosed as normal embryos by the conventional FISH method and be transferred, which might end with poor pregnancy outcomes, such as miscarriage or an affected offspring.
Array CGH also avoids many technical drawbacks inherent in the FISH method. One critical but difficult step is the fixation of a single cell onto a microscopic slide. 13, 26, 27 Also, the misdiagnosis may happen due to hybridization failure, suboptimal signal interpretation, such as overlapping signals or split signals. 13 Moreover, aCGH allows automation in data reading through computerized calculation of signal intensities, instead of interpreting the signals by eye in the FISH method, which may be subject to interoperator error. 13 Another advantage of aCGH is that it does not require preclinical validation prior to each IVF cycle, which is required for FISH. This avoids postponement of treatment. 3, 7, 28 Both allele dropout (ADO) and preferential amplification (PA) can decrease the reliability of PGD, especially for the autosomal dominant single gene disorder. 29 Because amplification failure of the affected allele will cause serious consequence, one solution is to analyze more loci near the targeted allele. 11, 29 From the previous studies published on single-cell multiple displacement amplification, the ADO rates and PA rates could reach as high as 25%. 29 If more loci are analyzed at the same time, ADO rates can be decreased to less than 10% and PA rates even lower. 29 Fiorentino et al also reported that when three short tandem repeat markers are put in either side of the translocation breakpoints, the failure rate of the test is about 0.002%, which happens only when ADO occurs in all markers at the same time. 12 For carriers of chromosomal translocation, the aberrant chromosomal segments of the unbalanced gametes are much larger, which usually involve more than four or five continuous probes on the microarray platform. Therefore the incidence of co-amplification failure of all four or five probes should also be low.
The smallest aberration detected in our study was a 1.6 Mbp deletion, which is better than FISH or even the traditional metaphase CGH (5e10 Mbp), 1 providing a convincible and satisfactory screening resolution with this technique. The cost of FISH is US$2167 in our center, no matter how many embryos are analyzed. The cost of aCGH depends on the number of analyzed embryos and is US$600/ embryo. The average number of analyzed embryos is 5.1, giving an average cost of around US$3000 in our study. Therefore it is often more expensive to perform aCGH than FISH and both the cost and the benefits should be discussed with the patients in clinical practice. b-hCG Z b-human chorionic gonadotropin; FHB Z fetal heart beat.
a Ongoing pregnancy was defined as the presence of fetal heart beat until 12 weeks of gestation. The best timing for embryo biopsy is still controversial. It has been well documented that as many as 66e87% of cleavage stage embryos exhibit mosaicism, 26, 30 which means there are at least two different cell lines in one embryo. Therefore sampling only one blastomere at an early developmental stage may not represent the final genetic composition and predict the real destiny of the embryo. 26, 30 By contrast, sampling several cells (usually 5e10 cells) during blastocyst biopsy can provide more genetic material for analysis, decreasing the risk of misdiagnosis due to mosaicism, amplification failure, and allele drop-out phenomenon. 9 It is assumed that performing biopsy on the trophectoderm, which is extraembryonic and develops into placental tissue, is less harmful to embryo viability than Day 3 blastomere biopsy. 9, 13, 14, 31 Moreover, it is also highly cost-effective that only competent embryos capable of developing to blastocysts and with highest implantation potential are biopsied. 9, 18 With the advance of modern laboratory techniques, the successful rate of blastocyst culture and cryopreservation has yielded improving and satisfying results. 5, 31, 32 Embryo cryopreservation and thawed ET has become the new trend of ART with many advantages. First, it can decrease the risk of ovarian hyperstimulation syndrome. 33 Second, because PGD is usually performed at a limited number of specialized genetic laboratories, thawed ET provided ample time to transport the biopsied samples from the remote infertility clinic and to perform genetic diagnosis. 7 Third, it has been shown that the endocrionological status and the uterine receptivity are altered by ovarian stimulation. That may decrease the implantation potential in a fresh transfer cycle, especially in a high responder.
34e36 ET in a subsequent thawed cycle can provide a more natural and synchronized endometrial environment for embryonic implantation. 13, 31 Our data also showed a high implantation rate of 50%.
In summary, for carriers with chromosomal translocations, our study describes an feasible PGD strategy, applying blastocyst biopsy, aCGH, embryo cryopreservation, and thawed ET. aCGH can provide comprehensive 24-chromosome analysis and the ongoing pregnancy rate was 50%/PGD cycle in our study, which seems to be higher than previous studies using FISH methods. There was no case of miscarriage. Although the number of the patients in our study is too small to draw robust conclusions, the preliminary results may support a promising choice of future PGD treatment for these patients.
